Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Other hematologic neoplasm 2Sarcoma 1Myeloid 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × STA 9090 × Thoracic × Clear all
NCT01798485 2016-07-01

Galaxy 2

Synta Pharmaceuticals Corp.

Phase 3 Terminated
696 enrolled 28 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01562015 2015-05-20

CHIARA

Synta Pharmaceuticals Corp.

Phase 2 Completed
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01031225 2014-09-19

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 2 Completed
113 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡